DOCSLIB.ORG

Sixth Immunotherapy of Cancer Conference (ITOC): Advances and Perspectives—A Meeting Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sixth Immunotherapy of Cancer Conference (ITOC): Advances and Perspectives—A Meeting Report Open access Meeting report J Immunother Cancer: first published as 10.1136/jitc-2019-000268 on 28 February 2020. Downloaded from Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives—a meeting report Catarina Pinto,1 Michael Bergmann,2 Daria Briukhovetska,3 Volkmar Nuessler,3,4 Mario Sznol,5 Michael von Bergwelt- Baildon,6,7 Sebastian Kobold3,7 To cite: Pinto C, Bergmann M, ABSTRACT of reactive oxygen species (ROS). Moreover, Briukhovetska D, et al. Sixth Immunotherapy has moved to the forefront of cancer cancer cells may mechanically resist cell lysis by Immunotherapy of Cancer treatment, illustrated by the accelerating pace of novel myosin- based contraction. conference (ITOC): advances and therapy approvals. In this complex environment, scientists perspectives—a meeting report. While studying T cell metabolism, Pedro rely on cutting edge conferences to stay informed. Journal for ImmunoTherapy Romero revealed that memory T cells are The Immunotherapy of Cancer (ITOC) conference was of Cancer 2020;8:e000268. essential for melanoma control. VLA1+ tumor- doi:10.1136/jitc-2019-000268 established jointly with the Society of the Immunotherapy of Cancer to bring the European researchers together. In its infiltrating lymphocytes (TILs) controlled sixth edition, the ITOC conference has recently been held the tumor outgrowth and were found to coex- ► Additional material is in Vienna, Austria. press CD69 and CD103, indicating a tissue- published online only. To view + + please visit the journal online resident phenotype. Additionally, TCF1 CD8 (http:// dx. doi. org/ 10. 1136/ jitc- memory T cell frequency in patient samples 2019- 000268). PREFACE correlated with a good prognosis. The past years have seen an explosion in the Lisa Derosa identified that Akkermansia CP, MB and DB contributed number of indications approved for immu- muciniphila and Bacteroides salyersiae present equally. notherapeutic modalities and new clinical 1 2 in the stool of non- small- cell lung carci- Accepted 19 December 2019 trials. The present report highlights the noma (NSCLC) and renal cell carcinoma novel aspects presented during the plenary patients are associated with favorable clinical sessions (figure 1). This year Immunotherapy responses to treatment. In murine models, of Cancer (ITOC) dedicated a lifetime award these species reversed resistance to PD-1/ to Alberto Mantovani to recognize his input CTLA-4 blockade after fecal transplantation to the understanding of the mechanisms of from non- responder patients. innate immunity and inflammation in cancer. http://jitc.bmj.com/ EMERGING CONCEPTS AND NEW AGENTS MICROENVIRONMENT AND METABOLISM Using single-cell RNA profiles, Ana Anderson found that checkpoint blockade therapy- Emanuel Donnadieu observed that T cells - actively excluded from the tumor accumulate induced transcriptional changes in Tim-3 PD-1-CD8+ TILs. Memory precursor subset in the peritumoral region. Ex vivo microscopy - on September 26, 2021 by guest. Protected copyright. + of those TILs identified as CD62L Slamf- revealed that CD206 macrophages reduce T hi - cell motility, and dense matrix fibers prevent 7 CX3CR1 the population is controlled cell infiltration. However, ICAM1 expres- by TCF1, and its loss limits the response to sion on the tumor cells promoted CAR T cell checkpoint blockade. infiltration. Paolo Ascierto showed that elevated expres- Eduard Batlle observed that cancer- associated sion of CD73 and its activity correlates with fibroblast cell programme is associated with a low response rate to nivolumab and ipilim- © Author(s) (or their umab treatment. This concept was previously employer(s)) 2020. Re- use prognosis in colorectal cancer (CRC) and permitted under CC BY-NC. No driven by transforming growth factor- beta found valid for melanoma patients and is commercial re- use. See rights (TGF-β) signaling. Model of mouse CRC using currently tested in prostate cancer. and permissions. Published by Claudia Lengerke showed that chemotherapy- BMJ. organoids with Lgr5, APC, KRAS, Tgfbr2, and Trp53 mutations demonstrated therapeutic resistant LSCs lack NKG2D ligands that are For numbered affiliations see necessary for NKG2D-mediated natural killer end of article. effects of TGF-β neutralization. Bo Huang demonstrated that PCK1- mediated (NK) cell killing. PARP1 suppresses the Correspondence to gluconeogenesis is essential for memory T expression of those ligands, and its inhibitors Professor Sebastian Kobold; cell formation and maintenance through the could be used as therapeutic agents to control sebastian. kobold@ med. uni- leukemogenesis in acute myeloid leukemia. muenchen. de increase of reduced glutathione and decrease Pinto C, et al. J Immunother Cancer 2020;8:e000268. doi:10.1136/jitc-2019-000268 1 Open access J Immunother Cancer: first published as 10.1136/jitc-2019-000268 on 28 February 2020. Downloaded from Figure 1 Summary of the sessions presented at the sixth Immunotherapy of Cancer conference. CRP, C-r eactive protein; DC, dendritic cells; IL, interleukin; NK, natural killer; NSCLC, non- small- cell lung carcinoma; PD- L1, programmed death- ligand 1; RCC, renal cell carcinoma; SAR, synthetic agonist receptor; TGF-β, transforming growth factor-beta; TIL, tumor- infiltrating http://jitc.bmj.com/ lymphocyte; TRUCKS, T cells redirected for antigen-unr estricted cytokine-initiated killing. NKG2A, a receptor for HLA- E that suppresses NK cell Samir Khleif highlighted that the combination of OX40 function, is an attractive target for immunotherapy. Steph- agonists and programmed death-ligand 1 (PD- L1) anti- anie Cornen combined NKG2A blockade with cetuximab body therapy mutually inhibited each other. However, on September 26, 2021 by guest. Protected copyright. to target microsatellite stable colon cancer and head and MEK inhibition decreases T cell exhaustion, which can neck squamous cell carcinoma. potentially be used to enhance the therapeutic efficacy of Finally, glycosylation is shaping the interactions of OX40 agonists. cells with their microenvironment. Siglec-9 is a lectin Efficacy of IL-18 therapy is hampered by IL18- BP, a that is upregulated in different tumor entities, which soluble decoy receptor. Aaron Ring engineered a decoy- affect macrophage polarization. Heinz Läubli showed that resistant interleukin 18 (IL-18) variant that showed effi- tumor- specific antibodies coupled to sialidases are effec- cacy as a single agent and in combination with anti- PD1 tive at delaying tumor growth. antibodies in several tumor models eliciting memory like TCF1+ CD8+ T cells. IL-18 is also induced by PEGylated IL-10 (Peglio- COMBINATION THERAPY decakin), which has been shown to enhance immune Sjoerd van der Burg proposed to combine checkpoint activation when combined with anti-PD- L1 therapy. Aung inhibition with vaccines directed against human papillo- Naing presented data from a phase I trial supporting the mavirus in oropharyngeal cancers. Moreover, the combi- observed effect, but side effects raise safety concerns. nation of carboplatin and paclitaxel depleted myeloid Alan Melcher demonstrated that systemic administration cells, which effectively induced strong and sustained T of oncolytic reovirus induces immunogenic tumor cell cell responses. death. It avoids neutralizing antibodies utilizing protective 2 Pinto C, et al. J Immunother Cancer 2020;8:e000268. doi:10.1136/jitc-2019-000268 Open access J Immunother Cancer: first published as 10.1136/jitc-2019-000268 on 28 February 2020. Downloaded from cell carriage by monocytes, enhances their APC function, Immunoscore. It was used to identify CRC patients with a and improves the efficacy of checkpoint inhibitor blockade. high risk of recurrence. Alfred Budillon presented early phase clinical trials Alessandra Nardin performed analysis of PBMCs from suggesting that epigenetic modifiers can potentiate the patients treated with atezolizumab (PD-L1- blockade) response to checkpoint inhibitors. Histone- deacetylase in the POPLAR trial and revealed that the majority of inhibitor therapy appears to be associated with an unique neoantigen T cells were present in the patients increase in immunogenic cell death, a decrease in Tregs, that responded to treatment. Hence, tumor- specific T cells and downregulation of c- myc. could be used as a prognostic marker of therapy outcome. PRECLINIcaL MODELS CELL THERAPY Krijn Dijkstra cocultured peripheral-blood- derived T cells Lisa Butterfield presented the current advancements in the with patient- derived organoids to enrich tumor- reactive T development of next- generation cell therapies, including cells and analyze tumor- specific T cell responses to epithe- affinity- enhanced T cells (NY-ESO-1 c259 TCR in metastatic lial cancers. Such T cells showed no cross-reactivity with synovial sarcoma, H3.3K27M-specific TCR in diffuse healthy tissue organoids as assessed by CD137 expression. midline gliomas), combinatorial antigen recognition Using single- cell RNA sequencing, Bernard Thienpont CAR T cells, dendritic cell- based personalized multipep- presented the transcriptome clustering of cells that shape tide neoepitope vaccines. the microenvironment of NSCLC. He identified stromal Hinrich Abken presented T cells redirected for antigen- cells as the major contributor that are further divided into unrestricted cytokine- initiated killing that secret CAR- 52 clusters. The comprehensive data array is also available inducible IL-12 or IL-18 and target CEA antigen in for endothelial, epithelial, and immune cells in online
Load more

Recommended publications
  • Inflammation and Cancer: the Macrophage Connection
    32 MEDICINA - Volumen 67 - NºISSN (Supl. 0025-7680 II), 2007 International Symposium MEDICINA (Buenos Aires) 2007; 67 (Supl. II): 32-34 NEW DIRECTIONS IN CANCER MANAGEMENT Academia Nacional de Medicina Buenos Aires, 6-8 June 2007 INFLAMMATION AND CANCER: THE MACROPHAGE CONNECTION ALBERTO MANTOVANI Istituto Clinico Humanitas, Milán, Italia Abstract Macrophages are key orchestrators of chronic inflammation. They respond to microenvironmental signals with polarized genetic and functional programmes. M1 macrophages which are classically activated by microbial products and interferon-γ, are potent effector cells which kill microorganisms and tumors. In contrast, M2 cells, tune inflammation and adaptive immunity; promote cell proliferation by producing growth factors and products of the arginase pathway (ornithine and polyamines); scavenge debris by expressing scav- enger receptors; promote angiogenesis, tissue remodeling and repair. M1 and M2 cells represent simplified ex- tremes of a continuum of functional states. Available information suggests that TAM are a prototypic M2 popula- tion. M2 polarization of phagocytes sets these cells in a tissue remodelling, and repair mode. And orchestrate the smouldering and polarized chronic inflammation associated to established neoplasia. Recent studies have begun to address the central issue of the relationship between genetic events causing cancer and activation of pro-tumor inflammatory reactions. Rearrangement of the RET oncogene (RET/PTC) is a frequent, causative and sufficient event in papillary carcinoma of the thyroid. It was recently observed that RET/PTC activates a pro- inflammatory genetic programme in primary human thyrocytes, including in particular chemokines and chemokine receptors. These molecules are also expressed in vivo and more so in metastatic tumors. These results high- light a direct connection between an early, causative and sufficient oncogene rearrangement and activation of a pro-inflammatory programme in a human tumor.
    [Show full text]
  • Wandering Pathways in the Regulation of Innate Immunity and Inflammation
    WANDERING PATHWAYS IN THE REGULATION OF INNATE IMMUNITY AND INFLAMMATION Alberto Mantovani Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milan), Italy; Humanitas University, via Rita Levi Montalcini, 20090 Pieve Emanuele (Milan), Italy; The William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ. 1 Abstract Tumor-associated macrophages (TAM) have served as a paradigm of cancer-related inflammation. Moreover, investigations on TAM have led to the dissection of macrophage plasticity and polarization and to the discovery and analysis of molecular pathways of innate immunity, in particular cytokines, chemokines and PTX3 as a prototypic fluid phase pattern recognition molecule. Mechanisms of negative regulation are complex and include decoy receptors, receptor antagonists, anti-inflammatory cytokines and the signalling regulator IL-1R8. In this review, topics and open issues in relation to regulation of innate immunity and inflammation and specific issues are discussed: 1) how macrophage and neutrophil plasticity and polarization underlie diverse pathological conditions ranging from autoimmunity to cancer and may pave the way to innovative diagnostic and therapeutic approaches; 2) the key role of decoy receptors and negative regulators (e.g. IL-1R2, ACKR2, IL-1R8) in striking a balance between amplification of immunity and resolution versus uncontrolled inflammation and tissue damage; 3) role of humoral innate immunity, illustrated by PTX3, in resistance against selected microbes, regulation of inflammation and immunity and tissue repair, with implications for diagnostic and therapeutic translation. 2 1. Encounter with the big eaters: the good, the bad and the never ugly macrophage I trained as a physician scientist, spending a substantial part of my time in the lab, first at the Institute of General Pathology (Molecular Biology, in pioneering early days), then at the Mario Negri Institute (immunology, Dr.
    [Show full text]
  • Final Program Auspices
    Final program Auspices Under the auspices of: Supported by: 1 Committees SCIENTIFIC COORDINATOR Gabriella Sozzi (IRCCS National Cancer Institute, Milan, Italy) LOCAL SCIENTIFIC AND ORGANIZING COMMITTEE Giovanni Apolone (Scientific Director, IRCCS National Cancer Institute, Milan, Italy) Andrea Anichini (IRCCS National Cancer Institute, Milan, Italy) Mario Colombo (IRCCS National Cancer Institute, Milan, Italy) Filippo De Braud (IRCCS National Cancer Institute, Milan, Italy) Massimo Di Nicola (IRCCS National Cancer Institute, Milan, Italy) Andrea Ferrari (IRCCS National Cancer Institute, Milan, Italy) Marina Garassino (IRCCS National Cancer Institute, Milan, Italy) Marilena Iorio (IRCCS National Cancer Institute, Milan, Italy) Delia Mezzanzanica (IRCCS National Cancer Institute, Milan, Italy) Ugo Pastorino (IRCCS National Cancer Institute, Milan, Italy) Filippo Pietrantonio (IRCCS National Cancer Institute, Milan, Italy) Luca Roz (IRCCS National Cancer Institute, Milan, Italy) Elda Tagliabue (IRCCS National Cancer Institute, Milan, Italy) SIC SCIENTIFIC BOARD President Gabriella Sozzi (IRCCS National Cancer Institute, Milan, Italy) President Elect Nicola Normanno (National Cancer Institute “G. Pascale”, Naples, Italy) Board Paola Chiarugi (University of Florence, Italy) Amedeo Columbano (University of Cagliari, Italy) Rita Falcioni (Regina Elena National Cancer Institute, Rome, Italy) Davide Melisi (University of Verona, Italy) Katia Scotlandi (IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy) Elda Tagliabue (IRCCS National Cancer Institute,
    [Show full text]
  • Neutrophil 2016”
    Inflammation, Immunity and Cancer: Neutrophils and Other Leukocytes The Society For Leukocyte Biology’s 49th Annual Meeting and “Neutrophil 2016” September 15-17, 2016 • University of Verona Congress Center • Verona, Italy Program Book www.leukocytebiology.org Inflammation, Immunity and Cancer: Neutrophils and Other Leukocytes The Society For Leukocyte Biology’s 49th Annual Meeting and “Neutrophil 2016” Thank You to Our 2016 Sponsors SILVER SPONSOR SPECIAL THANKS Funding for this conference was made possible [in part] by 1 R13 AI124612-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. BRONZE SPONSORS CONTRIBUTING SPONSOR Welcome letter Dear Colleagues, It is our great pleasure to welcome you to this Joint Meeting of the Society for Leukocyte Biology (SLB) and Neutrophil 2016. In addition to an outstanding scientific program, the meeting is held in beautiful Verona, a city teeming with history from the Roman empire to the Middle Ages and Italian Renaissance (it is after all the home of Romeo and Juliet), to the Napoleonic and Austrian empires. The city and its region has numerous architectural gems of its rich past, and is located near the majestic Garda Lake and the world-renowned Valpolicella wine-producing area, dating back to Roman times. The theme for this year’s meeting is “Inflammation, Immunity and Cancer: Neutrophils and Other Leukocytes.” Our Keynote Speaker, and recipient of the Bonazinga award, is William Nauseef (University of Iowa).
    [Show full text]
  • IL-1 Signaling Member Serving As A
    Discovery of the DIGIRR Gene from Teleost Fish: A Novel Toll−IL-1 Receptor Family Member Serving as a Negative Regulator of IL-1 Signaling This information is current as of October 1, 2021. Yi-feng Gu, Yu Fang, Yang Jin, Wei-ren Dong, Li-xin Xiang and Jian-zhong Shao J Immunol 2011; 187:2514-2530; Prepublished online 29 July 2011; doi: 10.4049/jimmunol.1003457 Downloaded from http://www.jimmunol.org/content/187/5/2514 Supplementary http://www.jimmunol.org/content/suppl/2011/07/29/jimmunol.100345 Material 7.DC1 http://www.jimmunol.org/ References This article cites 87 articles, 26 of which you can access for free at: http://www.jimmunol.org/content/187/5/2514.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 1, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Discovery of the DIGIRR Gene from Teleost Fish: A Novel Toll–IL-1 Receptor Family Member Serving as a Negative Regulator of IL-1 Signaling Yi-feng Gu, Yu Fang, Yang Jin, Wei-ren Dong, Li-xin Xiang, and Jian-zhong Shao Toll–IL-1R (TIR) family members play crucial roles in a variety of defense, inflammatory, injury, and stress responses.
    [Show full text]
  • Il-1 and Il-1 Regulatory Pathways in Cancer Progression And
    1 Immunol Rev. – IL-1 AND IL-1 REGULATORY PATHWAYS IN CANCER PROGRESSION AND THERAPY Alberto Mantovani1,2,3,*, Isabella Barajon2 and Cecilia Garlanda1,2 1Humanitas Clinical and Research Center, via Manzoni 56, 20089 Rozzano (Milan), Italy; 2Humanitas University, via Rita Levi Montalcini 4, 20090 Pieve Emanuele (Milan), Italy; 3The William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ. *Correspondence: Alberto Mantovani Tel 0039 02 82242445 FAX 0039 02 82245101 [email protected] 2 Running title: IL-1 in cancer Abstract Inflammation is an important component of the tumor microenvironment. IL-1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL-1 is subject to regulation by components of the IL-1 and IL-1 receptor (ILR) families. Negative regulators include a decoy receptor (IL-1R2), receptor antagonists (IL-1Ra), IL-1R8, and anti-inflammatory IL-37. IL- 1 acts at different levels in tumor initiation and progression, including driving chronic non-resolving inflammation, tumor angiogenesis, activation of the IL-17 pathway, induction of myeloid-derived suppressor cells (MDSC) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL-1 targeting deserves extensive analysis. Key words: interleukin-1, inflammation, inflammation-associated cancer, therapy 3 Introduction Selected chronic inflammatory conditions increase the risk of developing cancer (the extrinsic pathway) (1). These include infection, autoimmunity and autoinflammation. Colitis- associated cancer has served as a typical example of this connection. In the intrinsic pathway, genetic events, which drive carcinogenesis, orchestrate the construction of an inflammatory microenvironment by direct induction of inflammatory genes or through activation of downstream transcription factors (nuclear factor-κB (NF-κB), signal transducer and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1α (HIF-1α)).
    [Show full text]
  • A Model for Their Trafficking Chemokine Receptors During Dendritic
    c Cutting Edge: Differential Regulation of Chemokine Receptors During Dendritic Cell Maturation: A Model for Their Trafficking Properties1 Silvano Sozzani,2,3* Paola Allavena,2* Giovanna D’Amico,* Walter Luini,* Giancarlo Bianchi,* Motoji Kataura,† Toshio Imai,† Osamu Yoshie,† Raffaella Bonecchi,* and Alberto Mantovani*‡ known that DC trafficking is regulated. Bone marrow and blood Upon exposure to immune or inflammatory stimuli, dendritic DC progenitors seed nonlymphoid tissues, where they develop into cells (DC) migrate from peripheral tissues to lymphoid organs, immature DC with high ability to capture Ags. Immune and in- where they present Ag. CC chemokines induce chemotactic and flammatory signals induce mobilization of DC from the periphery transendothelial migration of immature DC, in vitro. Maturation to lymph nodes or spleen T cell areas and a shift from a “process- of DC by CD40L, or by LPS, IL-1, and TNF, induces down-reg- ing” to a “presenting” stage, characterized by an increased capacity ulation of the two main CC chemokine receptors expressed by to stimulate T lymphocytes (5–11). these cells, CCR1 and CCR5, and abrogates chemotaxis to their The current concept of the multistep process of leukocyte recruit- ligands. Inhibition was rapid (<1 h) and included the unrelated ment into tissues envisions chemotactic agonists as one of the key agent FMLP. Concomitantly, the expression of CCR7 and the effector molecules (12–14). Chemokines are a superfamily of chemo- migration to its ligand EBI1 ligand chemokine (ELC)/macro- tactic proteins that can be divided in four groups on the basis of a phage inflammatory protein (MIP)-3b, a chemokine expressed in cysteine structural motif.
    [Show full text]
  • Ovarian Carcinoma Macrophages Associated with Human
    Defective Expression of the Monocyte Chemotactic Protein-1 Receptor CCR2 in Macrophages Associated with Human Ovarian Carcinoma This information is current as of September 24, 2021. Antonio Sica, Alessandra Saccani, Barbara Bottazzi, Sergio Bernasconi, Paola Allavena, Brancatelli Gaetano, Francesca Fei, Graig LaRosa, Chris Scotton, Frances Balkwill and Alberto Mantovani J Immunol 2000; 164:733-738; ; Downloaded from doi: 10.4049/jimmunol.164.2.733 http://www.jimmunol.org/content/164/2/733 http://www.jimmunol.org/ References This article cites 53 articles, 20 of which you can access for free at: http://www.jimmunol.org/content/164/2/733.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Defective Expression of the Monocyte Chemotactic Protein-1 Receptor CCR2 in Macrophages Associated with Human Ovarian Carcinoma1 Antonio Sica,2* Alessandra Saccani,* Barbara Bottazzi,* Sergio Bernasconi,* Paola Allavena,* Brancatelli Gaetano,† Francesca Fei,† Graig LaRosa,‡ Chris Scotton,§ Frances Balkwill,§ and Alberto Mantovani*¶ Monocyte chemotactic protein-1 (MCP-1, CCL2) is an important determinant of macrophage infiltration in tumors, ovarian carcinoma in particular.
    [Show full text]
  • Scavenging of Inflammatory CC Chemokines by the Promiscuous Putatively Silent Chemokine Receptor D6
    Cutting Edge: Scavenging of Inflammatory CC Chemokines by the Promiscuous Putatively Silent Chemokine Receptor D6 This information is current as Anna M. Fra, Massimo Locati, Karel Otero, Marina Sironi, of October 4, 2021. Paola Signorelli, Maria L. Massardi, Marco Gobbi, Annunciata Vecchi, Silvano Sozzani and Alberto Mantovani J Immunol 2003; 170:2279-2282; ; doi: 10.4049/jimmunol.170.5.2279 http://www.jimmunol.org/content/170/5/2279 Downloaded from References This article cites 19 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/170/5/2279.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 4, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY CUTTING EDGE Cutting Edge: Scavenging of Inflammatory CC Chemokines by the Promiscuous Putatively Silent Chemokine Receptor D61 Anna M. Fra,2* Massimo Locati,2† Karel Otero,‡ Marina Sironi,‡ Paola Signorelli,† Maria L.
    [Show full text]
  • Achille Anselmo
    Curriculum Vitae Achille Anselmo INFORMAZIONI PERSONALI Achille Anselmo Milano, Italia [email protected] Sesso: Maschio | Data di nascita 30/08/1979 | Nazionalità Italiana TITOLO DI STUDIO Dottore di ricerca in Scienze farmacotossicologiche, farmacognostiche e biotecnologie POSIZIONE RICOPERTA farmaceutiche RUOLO IN SOMA Docente del corso di Chimica e Biochimica ESPERIENZA PROFESSIONALE Dal 01 Aprile 2006 Tecnologo ricercatore presso Fondazione Humanitas per la Ricerca, via Manzoni 103/A Rozzano, Milano. Settore ricerca e sviluppo Dal 30 Settembre 2017 al 30 Docente di Chimica (A034) presso istituto professionale V. Kandinskij, Milano Giugno 2020 Ottobre 2011 EFIS Fellowship, UniversitY of Debrecen (Ungheria) Titolo del progetto: Molecular mechanisms involved in the Cross-talk between chemokine receptors andintegrins analYzed bY floW cYtometric FRET Ottobre 2010 UICC TechnologY Transfer, UniversitY of Debrecen (Ungheria) Titolo del progetto: Cross-talk between chemokines receptors and integrins analyzed by floW cYtometric FRET technology in human tumor cells. Dal 30 Settembre 2005 al 31 Docente di Cultura medico sanitaria (A015) presso istituto professionale V. Kandinskij, Marzo 2006 Milano Dal 1 Gennaio 2004 al 31 Borsista presso il laboratorio di biologia cellulare e biochimica dell’aterotrombosi del Centro Marzo 2006 Cardiologico Fondazione Monzino, via Parea 4, Milano. Titolo del progetto: identificazione di proteine coinvolte nell’aterosclerosi in distretti vascolari. ISTRUZIONE E FORMAZIONE Dal 2005 al 2007 Dottorato di
    [Show full text]
  • PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer
    Article PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer Graphical Abstract Authors Eduardo Bonavita, Stefania Gentile, ..., Cecilia Garlanda, Alberto Mantovani Correspondence [email protected] (C.G.), [email protected] (A.M.) In Brief PTX3 deficiency triggers Complement- dependent tumor-promoting inflammation, with enhanced tumor burden, macrophage infiltration, cytokine production, angiogenesis, and genetic instability, revealing the role of this innate immunity mediator as an extrinsic oncosuppressor. Highlights d PTX3 deficiency unleashes Complement-dependent tumor- promoting inflammation d Tumors developed in a PTX3-deficient context have higher frequency of mutated Trp53 d PTX3 expression is epigenetically repressed in selected human tumors d Complement is an essential component of tumor-promoting inflammation Bonavita et al., 2015, Cell 160, 700–714 February 12, 2015 ª2015 Elsevier Inc. http://dx.doi.org/10.1016/j.cell.2015.01.004 Article PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer Eduardo Bonavita,1 Stefania Gentile,1 Marcello Rubino,1 Virginia Maina,1 Roberto Papait,1,2 Paolo Kunderfranco,1 Carolina Greco,1 Francesca Feruglio,1 Martina Molgora,1 Ilaria Laface,1 Silvia Tartari,1 Andrea Doni,1 Fabio Pasqualini,1 Elisa Barbati,1 Gianluca Basso,1 Maria Rosaria Galdiero,1 Manuela Nebuloni,3 Massimo Roncalli,1 Piergiuseppe Colombo,1 Luigi Laghi,1 John D. Lambris,4 Se´ bastien Jaillon,1 Cecilia Garlanda,1,* and Alberto
    [Show full text]
  • Ligands and Receptors of the Interleukin-1 Family In
    CORE Metadata, citation and similar papers at core.ac.uk EDITORIAL Provided by Frontiers - Publisher Connector published: 20 November 2013 doi: 10.3389/fimmu.2013.00396 Ligands and receptors of the interleukin-1 family in immunity and disease Cecilia Garlanda1 and Alberto Mantovani 1,2* 1 Department of Inflammation and Immunology, Humanitas Clinical and Research Center, Rozzano, Italy 2 Department of Biotechnology and Translational Medicine, University of Milan, Rozzano, Italy *Correspondence: [email protected] Edited by: Kendall A. Smith, Cornell University, USA Keywords: interleukin-1, decoy receptor, inflammation, innate immunity, adaptive immunity, autoinflammatory diseases IL-1 has served as a ground breaking molecule in immunology and relevance with respect to the different functions, as cytokines or as it is now experiencing a renaissance. Originally the description of DAMPs, played by IL-1 family members (10). a cytokine acting at vanishingly low concentration on cells and Members of IL-1R like receptor family include signaling mole- organs as diverse as the hypothalamus (fever) and T cells (1) was cules and negative regulators. In our review, we present the latter, without precedent in biology and paved the way to the whole field which include the prototypic decoy receptor type 2 IL-1R and of cytokines and their pleiotropic mode of action. “receptors” with regulatory function, such as TIR8/SIGIRR (11). The discovery of the importance of IL-1 in defense against bac- We suggest that the presence of multiple pathways of negative reg- teria and of the Toll-IL-1 resistance (TIR, as originally defined) ulation of members of the IL-1/IL-1R family emphasizes the need domain was upstream of the discovery of Toll-like receptors (2).
    [Show full text]